Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease

Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent, N Engl J Med., 345, 1098, 10.1056/NEJMoa011110 Obrador, 2003, Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab, Gas-troenterol Hepatol., 26, 29, 10.1016/S0210-5705(03)70338-0 Riestra, 2015, en representación de GETECCU: Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal, Enferm Inflam Intest Dia., 14, 109 Baddley, 2018, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents), Clin Microbiol Infect., 24 Winthrop, 2018, Clin Microbiol Infect., 24 Migliori, 2018, ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update, Eur Respir J., 51 Lewinsohn, 2017, Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children, Clin Infect., 64, 111, 10.1093/cid/ciw778 Getahun, 2015, Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries, Eur Resp J., 46, 1563, 10.1183/13993003.01245-2015 Handa, 2017, Tuberculosis and biologics in rheumatology: A special situation, Int J Rheum Dis., 20, 1313, 10.1111/1756-185X.13129 Cantini, 2015, Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice, Autoim Rev., 14, 503, 10.1016/j.autrev.2015.01.011 Lau, 2015, APLAR rheumatoid arthritis treatment recommendations, Int J Rheum Dis., 18, 685, 10.1111/1756-185X.12754 Poelman, 2019, Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update, J Cutan Med Surg, 23 Rodriguez-Jimenez, 2018, Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient, Actas Dermosifiliograf., 109, 584 Smith, 2017, British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017, Br J Dermatol., 177, 628, 10.1111/bjd.15665 Dheda, 2010, The immunology of tuberculosis: From bench to bedside, Respirology., 15, 433, 10.1111/j.1440-1843.2010.01739.x Furin, 2019, Tuberculosis, Lancet., 393, 1642, 10.1016/S0140-6736(19)30308-3 Informe epidemiológico sobre la situación de la tuberculosis en España, 2017. Madrid: Red Nacional de Epidemiología. Centro Nacional de Epidemiología. Instituto de Salud Carlos III; datos exportados el 06/05/2019. Zabana, 2008, Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy, Inflamm Bowel Dis., 14, 1387, 10.1002/ibd.20496 Arias-Guillen, 2014, T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease, Inflamm Bowel Dis., 20, 329, 10.1097/01.MIB.0000438429.38423.62 Marehbian, 2009, Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease, Am J Gastroenterol, 104, 2524, 10.1038/ajg.2009.322 Lorenzetti, 2014, Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials, Ann Med., 46, 547, 10.3109/07853890.2014.941919 Zabana, 2019, Relevant Infections in Inflammatory Bowel Disease, and Their Relationship With Immunosuppressive Therapy and Their Effects on Disease Mortality, J Crohns Colitis., 13, 828, 10.1093/ecco-jcc/jjz013 Loftus, 2017, Comparison of rates of active tuberculosis infection in the phase 2 and 3 clinical trial programs for anti-il12/23 and anti-TNFs, Gastroenterology, 152, S596, 10.1016/S0016-5085(17)32134-0 Ng, 2018, Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting, Inflamm Bowel Dis., 24, 2431, 10.1093/ibd/izy153 Maiga, 2012, Risk of tuberculosis reactivation with tofacitinib (CP-690550), J Infect Dis., 205, 1705, 10.1093/infdis/jis269 Winthrop, 2016, Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis, Ann Rheum Dis., 75, 1133, 10.1136/annrheumdis-2015-207319 Riestra, 2016, Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization, Rev Esp Enferm Dig., 108, 541, 10.17235/reed.2016.4440/2016 Gagnière, 2018, Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID), Aliment Pharmacol Ther., 48, 713, 10.1111/apt.14926 Rahier, 2014, Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohn’s Colitis., 8, 443, 10.1016/j.crohns.2013.12.013 Uzorka, 2019, Radiological Signs of Latent Tuberculosis on Chest Radiography: A Systematic Review and Meta-Analysis, Open Forum Infect Dis., 6, 10.1093/ofid/ofz313 Saidenberg-Kermanac´h N, 2012, Screening for latent tuberculosis in anti-TNF- candidate patients in a high tuberculosis incidence setting, Int J Tuberc Lung Dis, 16, 1307, 10.5588/ijtld.12.0111 Domínguez, 2018, Diagnosis and therapeutic approach of latent tuberculosis infection, Enferm Infecc Microbiol Clin., 36, 302, 10.1016/j.eimc.2017.11.014 Serre-Delcor, 2018, Sequential strategy for the LTBI screening of newly-arrived immigrants in vulnerable social situations, Enferm Infecc Microbiol Clin., 36, 550, 10.1016/j.eimc.2017.10.010 Farhat, 2006, False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?, Int J Tuberc Lung Dis., 10, 1192 Yeh, 2005, Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guerin vaccination in Taiwan, Trans R Soc Trop Med Hyg., 99, 509, 10.1016/j.trstmh.2005.03.001 Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR. 59(RR-5), 1–25. Kiray, 2009, Purified protein derivative response in juvenile idiopathic arthritis, J Rheumatol, 36, 2029, 10.3899/jrheum.090173 Mow, 2004, High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy, Clin Gastroenterol Hepatol., 2, 309, 10.1016/S1542-3565(04)00060-6 Wong, 2016, Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis, Thorax., 71, 64, 10.1136/thoraxjnl-2015-207811 Taxonera, 2017, Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease, J Crohn’s Colitis., 11, 792, 10.1093/ecco-jcc/jjx022 Li, 2017, Testing of tuberculosis infection among Chinese adolescents born after terminating the Bacillus Calmette-Guerin booster vaccination: subgroup analysis of a population-based cross-sectional study, Front Med., 11, 10.1007/s11684-017-0573-0 Carpio, 2016, Tuberculosis in anti-tumour necrosis factor treated inflammatory bowel disease patients after the implementation of preventive measures: Compliance with recommendations and safety of retreatment, J Crohn’s Colitis, 10, 1186, 10.1093/ecco-jcc/jjw022 Brown, 2017, Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results, Eur Respir J, 50, 10.1183/13993003.01267-2017 Kaur, 2018, Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease, Clin Gastroenterol Hepatol., 16, 10.1016/j.cgh.2017.11.038 Mariette, 2012, Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy, Ann Rheum Dis., 71, 1783, 10.1136/annrheumdis-2011-200408 Latorre, 2017, Immune-mediated inflammatory diseases differently affect IGRAs’ accuracy for latent tuberculosis infection diagnosis in clinical practice, PLoS One., 12, e0189202, 10.1371/journal.pone.0189202 Hamdi, 2006, Inhibition of antituberculosis T-lymphocyte function with tumour necrosis factor antagonists, Arthritis Res Ther., 8, R114, 10.1186/ar1994 van Zyl-Smit, 2009, Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review, PLoS One., 4, e8517, 10.1371/journal.pone.0008517 O’Shea, 2014, Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants, PLoS One., 9, e97366, 10.1371/journal.pone.0097366 Nemes, 2017, Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection, Am J Respir Crit Care Med., 196, 638, 10.1164/rccm.201704-0817OC Chee, 2010, Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens, Eur Respir J., 36, 355, 10.1183/09031936.00151309 Butera, 2009, New tools for detecting latent tuberculosis infection: Evaluation of RD1-specific long-term response, BMC Infect Dis., 9, 182, 10.1186/1471-2334-9-182 Schoepfer, 2008, Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease, Am J Gastroenterol., 103, 10.1111/j.1572-0241.2008.02050.x Bélard, 2011, Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection, Inflamm Bowel Dis., 17, 10.1002/ibd.21605 Papay, 2011, Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases, Inflamm Bowel Dis., 17, 84, 10.1002/ibd.21427 Qumseya, 2011, QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States, Inflamm Bowel Dis., 17, 77, 10.1002/ibd.21329 Andrisani, 2013, Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients, J Gastrointestin Liver Dis., 22, 21 Wong, 2014, Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients, Inflamm Bowel Dis., 20, 2067, 10.1097/MIB.0000000000000147 Çekiç, 2015, Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy, Ann Gastroenterol., 28, 241 Kurti, 2015, Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease, J Gastrointestin Liver Dis., 24, 467, 10.15403/jgld.2014.1121.244.bcg Cabriada, 2018, Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?, Turk J Gastroenterol., 29, 292, 10.5152/tjg.2018.17162 Al-Taweel, 2018, A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease, Dig Dis Sci., 63, 2695, 10.1007/s10620-018-5178-1 Amorim, 2019, Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil, Dig Dis Sci., 64, 1916, 10.1007/s10620-019-5475-3 Winthrop, 2012, You can’t always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need, Ann Rheum Dis, 71, 1757, 10.1136/annrheumdis-2012-201979 Park, 2018, Asian Organization for Crohn’s and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment, J Gastroenterol Hepatol, 33, 20, 10.1111/jgh.14019 Hsia, 2012, Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, Arth Rheum., 64, 2068, 10.1002/art.34382 Kleinert, 2012, Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-gamma release assays under real-life conditions, Ann Rheum Dis., 71, 1791, 10.1136/annrheumdis-2011-200941 Mir Viladrich, 2016, Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment, Arch Bronconeumol., 52, 36, 10.1016/j.arbres.2015.04.016 Abitbol, 2016, GETAID. negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort, J Crohns Colitis, 10, 1179, 10.1093/ecco-jcc/jjw129 Taxonera, 2018, Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease, J Crohn’s Colitis., 12, 1270, 10.1093/ecco-jcc/jjy104 Joven, 2006, Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response?, Ann Rheum Dis., 65, 699, 10.1136/ard.2005.040055 Cagatay, 2011, TNF-alpha antagonist therapy modify the tuberculin skin test response, Rheumatol Int., 31, 1147, 10.1007/s00296-010-1424-3 Chen, 2008, Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy, Arthritis Rheum., 59, 800, 10.1002/art.23705 Park, 2009, Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial, J Rheumatol., 36, 2158, 10.3899/jrheum.090150 Xie, 2011, A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy, Clin Exp Med., 11, 155, 10.1007/s10238-010-0123-4 Bermejo, 2013, How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study, Dig Liver Dis., 45, 733, 10.1016/j.dld.2013.03.005 Abreu, 2017, Serial tuberculosis screening in inflammatory bowel disease patients receiving anti-TNFα therapy, J Crohns Colitis, 11, 1223, 10.1093/ecco-jcc/jjx080 Lee, 2018, A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases, J Crohns Colitis., 12, 954, 10.1093/ecco-jcc/jjy057 Carmona, 2005, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis Rheum., 52, 1766, 10.1002/art.21043 Comstock, 1999, How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?, Int J Tuberc Lung Dis, 3, 847 Zenner, 2017, Treatment of latent tuberculosis infection: An updated network meta-analysis, Ann Intern Med., 167, 248, 10.7326/M17-0609 Anibarro, 2010, Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain, Int J Tuberc Lung Dis., 14, 701 Iannone, 2014, Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: International recommendations, J Rheumatol., 41, 41 Saukkonen, 2006, An official ATS statement: Hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med., 174, 935, 10.1164/rccm.200510-1666ST Menzies, 2018, Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults, N Engl J Med., 379, 440, 10.1056/NEJMoa1714283 Baciewicz, 2013, Update on rifampin, rifabutin, and rifapentine drug interactions, Curr Med Res Opin., 29, 1, 10.1185/03007995.2012.747952 Ena, 2005, Short-Course Therapy with Rifampin plus Isoniazid, Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysis, Clin Infect Dis., 40, 670, 10.1086/427802 Njie, 2018, Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis, Am J Prev Med, 55, 244, 10.1016/j.amepre.2018.04.030 Vaidya, 2019, Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal, Int J Rheumatol., 2019, 2034950, 10.1155/2019/2034950 Abreu, 2013, Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population, J Crohn’s Colitis., 7, e486, 10.1016/j.crohns.2013.03.004 Akyuz, 2019, Inflammatory bowel disease and mycobacteria: How much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?, Eur J Gastroenterol Hepatol., 31, 777, 10.1097/MEG.0000000000001403 Snast, 2019, Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review, Am J Clin Dermatol., 10.1007/s40257-019-00432-y British Thoracic Society Standards of Care Committee, 2005, BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment, Thorax, 60, 800, 10.1136/thx.2005.046797 Blackmore, 2008, Therapeutic Use of Infliximab in Tuberculosis to Control Severe Paradoxical Reaction of the Brain and Lymph Nodes, Clin Infect Dis., 47, e83, 10.1086/592695 Wallis, 2009, Adalimumab Treatment of Life‐Threatening Tuberculosis, Clin Infect Dis., 48, 1429, 10.1086/598504 Garcia Vidal, 2005, Paradoxical Response to Antituberculous Therapy in Infliximab-Treated Patients with Disseminated Tuberculosis, Clin Infect Dis., 40, 756, 10.1086/427941 Abreu, 2016, Reintroduction of anti-TNFα therapy after (or even during) anti-TNFα-associated tuberculosis in immune-mediated diseases, J Crohn’s Colitis., 10, 120, 10.1093/ecco-jcc/jjv172 Tubach, 2009, Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry, Arthritis Rheum., 60, 1884, 10.1002/art.24632 Masiá, 2014, Recurrence of active tuberculosis following resumption of anti-TNF-α therapy in a patient with Crohn’s disease, Int J Tuberc Lung Dis, 18, 249, 10.5588/ijtld.13.0751 Kisacik, 2016, Characteristics predicting tuberculosis risk under tumor necrosis factor-α inhibitors: Report from a large multicenter cohort with high background prevalence, J Rheumatol., 43, 524, 10.3899/jrheum.150177 Kim, 2016, Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: A retrospective nationwide registry of the Korean Society of spondyloarthritis research, PLoS One., 11, 1